| scholarly article | Q13442814 |
| P50 | author | Thomas E Morrison | Q66829484 |
| Mark T Heise | Q89544238 | ||
| Bronwyn M Gunn | Q91842985 | ||
| Alan C Whitmore | Q115653731 | ||
| P2093 | author name string | Alina R Lotstein | |
| Lauren Oko | |||
| Stephanie A Montgomery | |||
| Susan A Elmore | |||
| P2860 | cites work | Chikungunya virus takes centre stage in virally induced arthritis: possible cellular and molecular mechanisms to pathogenesis | Q37616326 |
| A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years | Q40372969 | ||
| A determinant of Sindbis virus neurovirulence enables efficient disruption of Jak/STAT signaling. | Q41946436 | ||
| Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. | Q42172413 | ||
| Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus | Q43038647 | ||
| Fever epidemic moves into Sri Lanka | Q43131384 | ||
| Complement receptor 3 promotes severe ross river virus-induced disease | Q43251027 | ||
| Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island | Q44851009 | ||
| An animal model for studying the pathogenesis of chikungunya virus infection | Q44851012 | ||
| Tenosynovitis and vascular disorders associated with Chikungunya virus-related rheumatism | Q44851274 | ||
| Chikungunya epidemic in India: a major public-health disaster | Q44851348 | ||
| Chikungunya virus infection. A retrospective study of 107 cases | Q44851815 | ||
| Natural history of Ross River virus-induced epidemic polyarthritis. | Q45730612 | ||
| A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease | Q21559504 | ||
| Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period | Q21562272 | ||
| Human muscle satellite cells as targets of Chikungunya virus infection | Q21562321 | ||
| Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages | Q24288996 | ||
| Ross River virus transmission, infection, and disease: a cross-disciplinary review | Q24550672 | ||
| Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling | Q24594497 | ||
| Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease | Q24682922 | ||
| Mayaro Virus Disease: An Emerging Mosquito‐Borne Zoonosis in Tropical South America | Q27183597 | ||
| The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic | Q27469278 | ||
| Chikungunya fever is transmitted locally in Europe for first time | Q27481060 | ||
| Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus | Q29620003 | ||
| Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies | Q33517926 | ||
| Chikungunya outbreaks--the globalization of vectorborne diseases | Q34002554 | ||
| Chikungunya virus arthritis in adult wild-type mice | Q34046030 | ||
| Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases | Q34087571 | ||
| Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response | Q34110965 | ||
| O'NYONG-NYONG FEVER: AN EPIDEMIC VIRUS DIESEASE IN EAST AFRICA. VII. VIRUS ISOLATIONS FROM MAN AND SEROLOGICAL STUDIES UP TO JULY 1961. | Q34260112 | ||
| Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis | Q34301840 | ||
| Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases | Q34579545 | ||
| Retrospective survey of Chikungunya disease in Réunion Island hospital staff | Q34618922 | ||
| Novel chikungunya virus variant in travelers returning from Indian Ocean islands | Q35792249 | ||
| Chikungunya fever: an epidemiological review of a re-emerging infectious disease | Q37575480 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chikungunya | Q243257 |
| myositis | Q1433212 | ||
| tenosynovitis | Q1505689 | ||
| viral persistence | Q44134905 | ||
| Chikungunya virus | Q15794049 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 32-40 | |
| P577 | publication date | 2010-12-23 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence | |
| P478 | volume | 178 |
| Q35675871 | A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation |
| Q36185161 | A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA Viruses |
| Q35602217 | A combination of doxycycline and ribavirin alleviated chikungunya infection |
| Q90263559 | A comparison of Chikungunya virus infection, progression, and cytokine profiles in human PMA-differentiated U937 and murine RAW264.7 monocyte derived macrophages |
| Q36897996 | A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs |
| Q92124331 | A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection |
| Q37643733 | A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. |
| Q92860171 | A possible role for autoimmunity through molecular mimicry in alphavirus mediated arthritis |
| Q26700129 | A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis |
| Q38329445 | A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization |
| Q34990686 | Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus |
| Q39458858 | Age has a role in driving host immunopathological response to alphavirus infection. |
| Q56897945 | An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope |
| Q30240216 | Animal Models of Chikungunya Virus Infection and Disease. |
| Q64904067 | Animal model of arthritis and myositis induced by the Mayaro virus. |
| Q66680697 | Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus |
| Q36292209 | Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models |
| Q40656579 | Antiviral Strategies Against Chikungunya Virus |
| Q63246307 | Arthritogenic Alphavirus-Induced Immunopathology and Targeting Host Inflammation as A Therapeutic Strategy for Alphaviral Disease |
| Q37713542 | Attenuating mutations in nsP1 reveal tissue-specific mechanisms for control of Ross River virus infection |
| Q34264257 | Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein |
| Q33861091 | BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1) |
| Q89650120 | Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus |
| Q24701763 | Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection |
| Q36318652 | Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress |
| Q34810471 | CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice. |
| Q24701757 | Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology |
| Q28551420 | Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses |
| Q27313456 | Characterization of chikungunya virus induced host response in a mouse model of viral myositis |
| Q30235585 | Chikungunya Infection: a Global Public Health Menace |
| Q39273197 | Chikungunya Virus. |
| Q38874607 | Chikungunya Virus: Current Perspectives on a Reemerging Virus. |
| Q34222718 | Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia |
| Q38118022 | Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy |
| Q36582816 | Chikungunya virus and prospects for a vaccine |
| Q89899047 | Chikungunya virus evades antiviral CD8+ T cell responses to establish persistent infection in joint-associated tissues |
| Q59350996 | Chikungunya virus fidelity variants exhibit differential attenuation and population diversity in cell culture and adult mice |
| Q39172123 | Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice |
| Q57023103 | Chikungunya virus impairs draining lymph node function by inhibiting HEV-mediated lymphocyte recruitment |
| Q38527379 | Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. |
| Q30235512 | Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies |
| Q24701786 | Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes |
| Q34378105 | Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response |
| Q90440599 | Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody |
| Q94458554 | Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross |
| Q59350720 | Defining a correlate of protection for chikungunya virus vaccines |
| Q35109218 | Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design |
| Q40254655 | Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice |
| Q61795509 | Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice |
| Q92982929 | Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA |
| Q30240191 | Development of Vaccines for Chikungunya Fever |
| Q35662507 | Development of a Hamster Model for Chikungunya Virus Infection and Pathogenesis. |
| Q27335008 | Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus |
| Q83227399 | Discrete viral E2 lysine residues and scavenger receptor MARCO are required for clearance of circulating alphaviruses |
| Q44169856 | Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology |
| Q30394063 | Dysregulated TGF-β Production Underlies the Age-Related Vulnerability to Chikungunya Virus |
| Q30516488 | Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein |
| Q93049068 | Establishment and Comparison of Pathogenicity and Related Neurotropism in Two Age Groups of Immune Competent Mice, C57BL/6J Using an Indian Isolate of Chikungunya Virus (CHIKV) |
| Q92072015 | Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate |
| Q24701758 | Expanding Regulatory T Cells Alleviates Chikungunya Virus-Induced Pathology in Mice |
| Q93101104 | Expression of the Mxra8 Receptor Promotes Alphavirus Infection and Pathogenesis in Mice and Drosophila |
| Q28656413 | Fingolimod treatment abrogates chikungunya virus–induced arthralgia |
| Q36303514 | Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus |
| Q59353759 | Genetic control of alphavirus pathogenesis |
| Q37900420 | Genomic evolution and phenotypic distinctions of Chikungunya viruses causing the Indian Ocean outbreak |
| Q39013750 | Immune-Mediated Protection and Pathogenesis of Chikungunya Virus |
| Q59350719 | In Vivo Evaluation of Withania somnifera-Based Indian Traditional Formulation ( Amukkara Choornam), Against Chikungunya Virus-Induced Morbidity and Arthralgia |
| Q35550114 | In vivo imaging of chikungunya virus in mice and Aedes mosquitoes using a Renilla luciferase clone |
| Q90633455 | In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease |
| Q47289858 | Inflammatory monocytes mediate control of acute alphavirus infection in mice. |
| Q40072937 | Interferon regulatory factor-1 (IRF-1) protects against chikungunya virus induced immunopathology by restricting infection in muscle cells |
| Q36200552 | Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. |
| Q42705670 | Limitations of Current in Vivo Mouse Models for the Study of Chikungunya Virus Pathogenesis |
| Q40088877 | Macrophages as target cells for Mayaro virus infection: involvement of reactive oxygen species in the inflammatory response during virus replication |
| Q93016784 | Mayaro Virus Infects Human Chondrocytes and Induces the Expression of Arthritis-Related Genes Associated with Joint Degradation |
| Q58696348 | Mayaro: an emerging viral threat? |
| Q41857816 | Molecular mechanisms involved in the pathogenesis of alphavirus-induced arthritis |
| Q51782788 | Mosquito saliva re-shapes alphavirus infection and immunopathogenesis. |
| Q40656589 | Mouse Models of Chikungunya Virus |
| Q37993737 | Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology |
| Q24701792 | Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection |
| Q64956568 | Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate. |
| Q93062220 | MyD88-dependent influx of monocytes and neutrophils impairs lymph node B cell responses to chikungunya virus infection via Irf5, Nos2 and Nox2 |
| Q35799153 | Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells |
| Q36483436 | Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis |
| Q26782722 | Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model) |
| Q36018504 | Novel Lesions of Bones and Joints Associated with Chikungunya Virus Infection in Two Mouse Models of Disease: New Insights into Disease Pathogenesis |
| Q21559402 | Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism |
| Q91842996 | Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes |
| Q64118754 | P38 and JNK Mitogen-Activated Protein Kinases Interact With Chikungunya Virus Non-structural Protein-2 and Regulate TNF Induction During Viral Infection in Macrophages |
| Q89577981 | Pathogenetic Potential Relating to Metabolic Activity in a Mouse Model of Infection with the Chikungunya Virus East/Central/South African Genotype |
| Q37214518 | Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence |
| Q58698800 | Plasmodium co-infection protects against chikungunya virus-induced pathologies |
| Q40207010 | Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201). |
| Q38586243 | Protective and Pathogenic Responses to Chikungunya Virus Infection |
| Q34790998 | Reovirus cell entry requires functional microtubules. |
| Q24701776 | Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice |
| Q35913875 | Serotonin Receptor Agonist 5-Nonyloxytryptamine Alters the Kinetics of Reovirus Cell Entry. |
| Q64892583 | Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs. |
| Q39030569 | Temporal Role for MyD88 in a Model of Brucella-Induced Arthritis and Musculoskeletal Inflammation |
| Q57010734 | The Interferon-Induced Exonuclease ISG20 Exerts Antiviral Activity through Upregulation of Type I Interferon Response Proteins |
| Q37252899 | The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses |
| Q93074227 | The NLRP3 inflammasome is involved with the pathogenesis of Mayaro virus |
| Q38745944 | The growth of arthralgic Ross River virus is restricted in human monocytic cells. |
| Q24276417 | The role of innate versus adaptive immune responses in a mouse model of O'nyong-nyong virus infection |
| Q28656412 | Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis |
| Q61446026 | controls chikungunya virus-specific pathogenic T cell IFNγ Th1 stimulation in mice |
| Q26314703 | γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease |
Search more.